Not strictly a treatment for rosacea, but it is interesting to note that this just-approved drug for the treatment of atopic dermatitis is the first new treatment in 10 years.
The way that crisaborole works to inhibit the PDE-4 enzyme active in eczema is not known – sound familiar ? A few proven rosacea treatments are not well understood.
Pfizer have just purchased the company that developed Eucrisa for an incredible $USD 5.2 billion. Analysts initially expected Allergan to purchase Anacor Pharmaceuticals, but Pfizer won out.
Wednesday, December 14, 2016 – 9:15pm EST
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) approved EUCRISATM (crisaborole) ointment 2%, a novel non-steroidal topical phosphodieterase-4 (PDE-4) inhibitor for the treatment of mild to moderate atopic dermatitis (AD) in patients two years of age and older.
AD, often called eczema, is a chronic condition impacting nearly 18 million children and adults in the United States. Approximately 90 percent of people living with AD have the mild to moderate form of the condition.
“The approval of EUCRISA is great news for the children and adults suffering from mild to moderate eczema, a community that has not had a new prescription treatment for more than 10 years,” said Albert Bourla, Group President, Pfizer Innovative Health.
EUCRISA is the first and only non-steroidal topical monotherapy that inhibits the PDE-4 enzyme in the skin. Overactive PDE-4 has been shown to contribute to the signs and symptoms of AD. The specific mechanism of action of crisaborole in AD is not well defined.
What is Eucrisa?
EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older.